Narrowing the Equity Gap: The Impact of California’s 2022 Medicaid Expansion on Access to SGLT-2 Inhibitors and GLP-1 RAs in Older Undocumented Immigrants
Posted inClinical Updates Diabetes & Endocrinology news Public Health

Narrowing the Equity Gap: The Impact of California’s 2022 Medicaid Expansion on Access to SGLT-2 Inhibitors and GLP-1 RAs in Older Undocumented Immigrants

This review analyzes the significant shift in type 2 diabetes prescribing patterns following California's 2022 Medi-Cal expansion, highlighting how policy-driven access to SGLT-2 inhibitors and GLP-1 receptor agonists narrowed health equity gaps for older undocumented populations.